Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021066 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
A Phase 1 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by SystImmune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 17
- Study locations
NCT07021066 is a Phase 1 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma that is actively recruiting participants, run by SystImmune. The registered enrollment target is 120 participants, below the 243-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (51% lower). The trial reports 17 study locations across 9 states.
The verdict
NCT07021066, a Phase 1 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by SystImmune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 17
- Study locations
Study Summary
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
Conditions Studied
Interventions
- DRUG BL-M05D1
Study Locations (17)
Texas
- NEXT Oncology- Austin - Austin
- NEXT Oncology- Dallas - Dallas
- MD Anderson - Houston
- NEXT Oncology San Antonio - San Antonio
- START Center for Care Center- San Antonio - San Antonio
- Baylor Scott and White Medical Center- Temple Clinic - Temple
Arizona
- Mayo Clinic Cancer Center- Phoenix - Phoenix
- HonorHealth - Scottsdale
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Institute - Detroit
Tennessee
- Sarah Cannon Research Institute - Oncology Partners - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Colorado
- University of Colorado Health - Aurora
Connecticut
- Yale Cancer Center - New Haven
Louisiana
- Ochsner Medical Center - New Orleans
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07021066
The ClinicalTrials.gov registry entry for NCT07021066 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (51% lower). The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which BL-M05D1 is the first listed.
NCT07021066 reports 17 study locations spanning 9 distinct geographic areas - top geographies include Texas, Arizona, Michigan.
Frequently Asked Questions
What is clinical trial NCT07021066 about?
NCT07021066 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors". The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
What is the current status of trial NCT07021066?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-07-30. Estimated completion is 2027-05-31.
What conditions does trial NCT07021066 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Other Solid Tumors.
What interventions are being tested in trial NCT07021066?
The interventions under investigation include: BL-M05D1 (DRUG).
Who is sponsoring clinical trial NCT07021066?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07021066 being conducted?
This trial has 17 study locations across Arizona, Colorado, Connecticut, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.